Updated on 23 July 2026
Medical systems aimed at increasing the efficacy of chemotherapy
Founder at Hlectron
Athens, Greece
About
Hlectron is developing two medical systems aimed at increasing the efficacy of chemotherapy. Our first generation system is based on a non invasive protocol and is monstrated to increase survival rates of breast cancer patients by 15%.
Our second generation is invasive and animal trials have demonstrated an increase in survival rates of 40% without administering any chemotherapy to the animals.
The technology is based on magnetic nano complexes and electromagnetic fields that increase the concentration and lifetime of free radicals.
Topic
- Healthcare innovations: HORIZON-MISS-2027-02-CANCER-05 Pre-commercial procurement of affordable solutions for healthcare systems in the areas of cancer technologies, cancer medical devices, or cancer medicines
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Type
- Partner seeks Consortium/Coordinator
Similar opportunities
Project cooperation
Clinical trial support and Research Collaboration
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Natalia Wilczyńska-Zawal
researcher at Jagiellonian University Medical College
Krakow, Poland
Project cooperation
Clinical Data Management and Biobanking Services
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Natalia Wilczyńska-Zawal
researcher at Jagiellonian University Medical College
Krakow, Poland
Project cooperation
(CANCER-03) GMP manufacturing and first-in-human trial delivery for rare-cancer therapeutics
- Partner seeks Consortium/Coordinator
- Clinical trials: HORIZON-MISS-2027-02-CANCER-03 Phase 1 including first-in-human clinical trials to test biomarker-guided medicines or multi-modal treatment interventions for patients with rare or very rare cancers or cancer subtypes
Ilias Nikolinakos
EU Grants and Funding Coordinator at Elpen Pharmaceutical Co. Inc.
Athens, Greece